Clinical trials: sponsored by Dana-Farber Cancer Institute
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody)…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- NCT06239220
- Testing
- PD-L1 t-haNK, Cetuximab, NAI
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC)
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery.
- Conditions
- Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
- Trial name
- NCT06664151
- Testing
- Fluzone Trivalent
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer
Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention
This trial will evaluate the SHARE-MC educational intervention designed to address sexual health needs and related adjustment in women with metastatic breast cancer.
- Trial name
- SHARE-MC (NCT07519200)
- Testing
- SHARE-MC, Informational Booklet
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Recurrent Endometrial Cancer
ALPINE: Maintenance Letrozole/Abemaciclib
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53)…
- Conditions
- Endometrial Cancer, Recurrent Endometrial Cancer, TP53
- Trial name
- NCT06366347
- Testing
- Abemaciclib, Letrozole, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cancer, Pain
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
- Trial name
- NCT06117709
- Testing
- I-STAMP
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkin's Lymphoma, Hodgkin's Disease
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different…
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders
- Trial name
- NCT00131014
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
Understanding Chronic Lymphocytic Leukemia
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
- Trial name
- NCT04028531
- Where
- United States
- Volunteers
- 2,750 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment.
- Trial name
- NCT07624513
- Testing
- Isatuximab, Iberdomide, Bortezomib (B)
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Dana-Farber Cancer Institute
HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival…
- Trial name
- NCT07513324
- Testing
- Pembroluzimab, Observation
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer
NeoVax With Nivolumab in Patients With Ovarian Cancer
This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.
- Trial name
- NCT04024878
- Testing
- Nivolumab, NeoVax, Core Needle Biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Breast Cancer Stage I
Taking AIM at Breast Cancer
The purpose of this research is to determine whether a 16-week exercise program for individuals with breast cancer and have completed treatment (i.e., surgery, chemotherapy, or radiation) for breast cancer will decrease…
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT04720209
- Testing
- CARE, TARE, Home-Based Stretching
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.
- Conditions
- HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer
- Trial name
- ADEPT (NCT04569747)
- Testing
- Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
- Where
- 32 sites in United States
- Volunteers
- 393 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Cancer, Financial Stress
PediRISE Feasibility
The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program…
- Conditions
- Pediatric Cancer, Financial Stress, Financial Hardship, Disparities
- Trial name
- NCT06283251
- Testing
- PediRISE Resource Program
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma…
- Trial name
- NCT04883671
- Testing
- Standard of Care, SBRT
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
HER-2 Positive Breast Cancer, Breast Cancer
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2.
- Conditions
- HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02326974
- Testing
- T-DM1, Pertuzumab, Excision of tumor/mastectomy
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- Dana-Farber Cancer Institute
Rectal Cancer, Colorectal Cancer
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.
- Conditions
- Rectal Cancer, Colorectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT06565052
- Testing
- Prehabilitation Program
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
This research study is evaluating a genomic analysis called Predictor Analysis of Microarray 50 (PAM50, by Prosigna®) as a tool to possibly guide the participant and the treating physician to choose the most personalized…
- Trial name
- NCT03749421
- Testing
- Prosigna PAM-50 assay
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
This is a Phase 1b and 2, open-label, single-arm study evaluating the safety, tolerability, and efficacy of roginolisib (IOA-244) in combination with obinutuzumab followed by venetoclax in patients with relapsed or refractory…
- Trial name
- NCT07847957
- Testing
- Roginolisib, Obinutuzumab, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute